It commonly happens in stock investing that investors miss the chance of buying winning stocks that they knew would stand out. Before they take the plunge, others get to know the hidden potential and enter into these stocks, pushing them out of reach.
So, instead of repenting, spotting the off-the-radar potential winners and immediately investing in them could be a smart decision.
One such company that looks well positioned for a solid gain, but has been overlooked by investors lately, is Derma Sciences Inc. DSCI. This Medical-Biomed/Genetics stock has actually seen estimates narrowed over the past month for the current fiscal year by about 80.0%. But that is not yet reflected in its price, as the stock lost 2.7% over the same time frame.
DERMA SCIENCES Price and Consensus
DERMA SCIENCES Price and Consensus | DERMA SCIENCES Quote
You should not be concerned about the price remaining muted going forward. This year’s expected earnings growth over the prior year is 94.5%, which should ultimately translate into price appreciation.
And if this isn’t enough, DSCI currently carries a Zacks Rank #2 (Buy) which further underscores the potential for its outperformance (See the performance of Zacks' portfolios and strategies here: About Zacks Performance).
So if you are looking for a stock flying under-the-radar that is well-equipped to bounce down the road, make sure to consider Derma Sciences. Solid estimate revisions and an impressive Zacks Rank suggest that better days may be ahead for DSCI and that now might be an interesting buying opportunity.
Confidential from Zacks
Beyond this Tale of the Tape, would you like to see Zacks' best recommendations that are not available to the public? Our Executive VP, Steve Reitmeister, knows when key trades are about to be triggered and which of our experts has the hottest hand. Click to see them now>>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
DERMA SCIENCES (DSCI): Free Stock Analysis Report
To read this article on Zacks.com click here.